Selected research
Industry Research
Irbesartan Industry Research Report 2026
Market perspective
The global Irbesartan market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Irbesartan is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Irbesartan is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Irbesartan is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Irbesartan include Angita Pharma, Apotex, Auro Pharma, Avanstra, BMS, Hanall, Shionogi, Sumitomo Dainippon Pharma and Taj Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Irbesartan market in terms of revenue (US$ million) and, where applicable, sales volume (Kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Kg) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Irbesartan Market by Company
Angita Pharma
Apotex
Auro Pharma
Avanstra
BMS
Hanall
Shionogi
Sumitomo Dainippon Pharma
Taj Pharmaceuticals
Verdant Life Sciences
Jiangsu Hengrui Medicine
Jiangsu Wangao Pharmaceutical
CTTQ
Novartis
Sanofi
Teva
Tianjin Huairen Pharmaceutical
Xiansheng Pharmaceutical
Yuanhe Pharmaceutical
Zhejiang Ainuo Pharmaceutical
Zhejiang Huahai Pharmaceutical
Zhuhai Rundu Pharma
Irbesartan Segment by Type
Combination Drugs
Prescribed Drugs
Irbesartan Segment by Application
Heart Failure
Fibrous Fibrillation
Kidney Disease
Hyperlipidemia
High Blood Pressure
Other
Irbesartan Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Irbesartan market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Irbesartan and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Irbesartan.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Irbesartan manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Irbesartan by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Irbesartan in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Combination Drugs
- Prescribed Drugs
Applications
- Heart Failure
- Fibrous Fibrillation
- Kidney Disease
- Hyperlipidemia
- High Blood Pressure
- Other
Companies covered
- Angita Pharma
- Apotex
- Auro Pharma
- Avanstra
- BMS
- Hanall
- Shionogi
- Sumitomo Dainippon Pharma
- Taj Pharmaceuticals
- Verdant Life Sciences
- Jiangsu Hengrui Medicine
- Jiangsu Wangao Pharmaceutical
- CTTQ
- Novartis
- Sanofi
- Teva
- Tianjin Huairen Pharmaceutical
- Xiansheng Pharmaceutical
- Yuanhe Pharmaceutical
- Zhejiang Ainuo Pharmaceutical
- Zhejiang Huahai Pharmaceutical
- Zhuhai Rundu Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Irbesartan Market Size (2021-2032)
- 2.2.2 Global Irbesartan Sales (2021-2032)
- 2.2.3 Global Irbesartan Market Average Price (2021-2032)
- 2.3 Irbesartan by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Combination Drugs
- 2.3.3 Prescribed Drugs
- 2.4 Irbesartan by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Heart Failure
- 2.4.3 Fibrous Fibrillation
- 2.4.4 Kidney Disease
- 2.4.5 Hyperlipidemia
- 2.4.6 High Blood Pressure
- 2.4.7 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Irbesartan Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Irbesartan Sales (Kg) of Manufacturers (2021-2026)
- 3.3 Global Irbesartan Revenue of Manufacturers (2021-2026)
- 3.4 Global Irbesartan Average Price by Manufacturers (2021-2026)
- 3.5 Global Irbesartan Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Irbesartan, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Irbesartan, Product Type & Application
- 3.8 Global Manufacturers of Irbesartan, Established Date
- 3.9 Global Irbesartan Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Angita Pharma
- 4.1.1 Angita Pharma Company Information
- 4.1.2 Angita Pharma Business Overview
- 4.1.3 Angita Pharma Irbesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Angita Pharma Irbesartan Product Portfolio
- 4.1.5 Angita Pharma Recent Developments
- 4.2 Apotex
- 4.2.1 Apotex Company Information
- 4.2.2 Apotex Business Overview
- 4.2.3 Apotex Irbesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Apotex Irbesartan Product Portfolio
- 4.2.5 Apotex Recent Developments
- 4.3 Auro Pharma
- 4.3.1 Auro Pharma Company Information
- 4.3.2 Auro Pharma Business Overview
- 4.3.3 Auro Pharma Irbesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Auro Pharma Irbesartan Product Portfolio
- 4.3.5 Auro Pharma Recent Developments
- 4.4 Avanstra
- 4.4.1 Avanstra Company Information
- 4.4.2 Avanstra Business Overview
- 4.4.3 Avanstra Irbesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Avanstra Irbesartan Product Portfolio
- 4.4.5 Avanstra Recent Developments
- 4.5 BMS
- 4.5.1 BMS Company Information
- 4.5.2 BMS Business Overview
- 4.5.3 BMS Irbesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 BMS Irbesartan Product Portfolio
- 4.5.5 BMS Recent Developments
- 4.6 Hanall
- 4.6.1 Hanall Company Information
- 4.6.2 Hanall Business Overview
- 4.6.3 Hanall Irbesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Hanall Irbesartan Product Portfolio
- 4.6.5 Hanall Recent Developments
- 4.7 Shionogi
- 4.7.1 Shionogi Company Information
- 4.7.2 Shionogi Business Overview
- 4.7.3 Shionogi Irbesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Shionogi Irbesartan Product Portfolio
- 4.7.5 Shionogi Recent Developments
- 4.8 Sumitomo Dainippon Pharma
- 4.8.1 Sumitomo Dainippon Pharma Company Information
- 4.8.2 Sumitomo Dainippon Pharma Business Overview
- 4.8.3 Sumitomo Dainippon Pharma Irbesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Sumitomo Dainippon Pharma Irbesartan Product Portfolio
- 4.8.5 Sumitomo Dainippon Pharma Recent Developments
- 4.9 Taj Pharmaceuticals
- 4.9.1 Taj Pharmaceuticals Company Information
- 4.9.2 Taj Pharmaceuticals Business Overview
- 4.9.3 Taj Pharmaceuticals Irbesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Taj Pharmaceuticals Irbesartan Product Portfolio
- 4.9.5 Taj Pharmaceuticals Recent Developments
- 4.10 Verdant Life Sciences
- 4.10.1 Verdant Life Sciences Company Information
- 4.10.2 Verdant Life Sciences Business Overview
- 4.10.3 Verdant Life Sciences Irbesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Verdant Life Sciences Irbesartan Product Portfolio
- 4.10.5 Verdant Life Sciences Recent Developments
- 4.11 Jiangsu Hengrui Medicine
- 4.11.1 Jiangsu Hengrui Medicine Company Information
- 4.11.2 Jiangsu Hengrui Medicine Business Overview
- 4.11.3 Jiangsu Hengrui Medicine Irbesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Jiangsu Hengrui Medicine Irbesartan Product Portfolio
- 4.11.5 Jiangsu Hengrui Medicine Recent Developments
- 4.12 Jiangsu Wangao Pharmaceutical
- 4.12.1 Jiangsu Wangao Pharmaceutical Company Information
- 4.12.2 Jiangsu Wangao Pharmaceutical Business Overview
- 4.12.3 Jiangsu Wangao Pharmaceutical Irbesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Jiangsu Wangao Pharmaceutical Irbesartan Product Portfolio
- 4.12.5 Jiangsu Wangao Pharmaceutical Recent Developments
- 4.13 CTTQ
- 4.13.1 CTTQ Company Information
- 4.13.2 CTTQ Business Overview
- 4.13.3 CTTQ Irbesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 CTTQ Irbesartan Product Portfolio
- 4.13.5 CTTQ Recent Developments
- 4.14 Novartis
- 4.14.1 Novartis Company Information
- 4.14.2 Novartis Business Overview
- 4.14.3 Novartis Irbesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Novartis Irbesartan Product Portfolio
- 4.14.5 Novartis Recent Developments
- 4.15 Sanofi
- 4.15.1 Sanofi Company Information
- 4.15.2 Sanofi Business Overview
- 4.15.3 Sanofi Irbesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Sanofi Irbesartan Product Portfolio
- 4.15.5 Sanofi Recent Developments
- 4.16 Teva
- 4.16.1 Teva Company Information
- 4.16.2 Teva Business Overview
- 4.16.3 Teva Irbesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Teva Irbesartan Product Portfolio
- 4.16.5 Teva Recent Developments
- 4.17 Tianjin Huairen Pharmaceutical
- 4.17.1 Tianjin Huairen Pharmaceutical Company Information
- 4.17.2 Tianjin Huairen Pharmaceutical Business Overview
- 4.17.3 Tianjin Huairen Pharmaceutical Irbesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Tianjin Huairen Pharmaceutical Irbesartan Product Portfolio
- 4.17.5 Tianjin Huairen Pharmaceutical Recent Developments
- 4.18 Xiansheng Pharmaceutical
- 4.18.1 Xiansheng Pharmaceutical Company Information
- 4.18.2 Xiansheng Pharmaceutical Business Overview
- 4.18.3 Xiansheng Pharmaceutical Irbesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 Xiansheng Pharmaceutical Irbesartan Product Portfolio
- 4.18.5 Xiansheng Pharmaceutical Recent Developments
- 4.19 Yuanhe Pharmaceutical
- 4.19.1 Yuanhe Pharmaceutical Company Information
- 4.19.2 Yuanhe Pharmaceutical Business Overview
- 4.19.3 Yuanhe Pharmaceutical Irbesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.19.4 Yuanhe Pharmaceutical Irbesartan Product Portfolio
- 4.19.5 Yuanhe Pharmaceutical Recent Developments
- 4.20 Zhejiang Ainuo Pharmaceutical
- 4.20.1 Zhejiang Ainuo Pharmaceutical Company Information
- 4.20.2 Zhejiang Ainuo Pharmaceutical Business Overview
- 4.20.3 Zhejiang Ainuo Pharmaceutical Irbesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.20.4 Zhejiang Ainuo Pharmaceutical Irbesartan Product Portfolio
- 4.20.5 Zhejiang Ainuo Pharmaceutical Recent Developments
- 4.21 Zhejiang Huahai Pharmaceutical
- 4.21.1 Zhejiang Huahai Pharmaceutical Company Information
- 4.21.2 Zhejiang Huahai Pharmaceutical Business Overview
- 4.21.3 Zhejiang Huahai Pharmaceutical Irbesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.21.4 Zhejiang Huahai Pharmaceutical Irbesartan Product Portfolio
- 4.21.5 Zhejiang Huahai Pharmaceutical Recent Developments
- 4.22 Zhuhai Rundu Pharma
- 4.22.1 Zhuhai Rundu Pharma Company Information
- 4.22.2 Zhuhai Rundu Pharma Business Overview
- 4.22.3 Zhuhai Rundu Pharma Irbesartan Sales, Revenue and Gross Margin (2021-2026)
- 4.22.4 Zhuhai Rundu Pharma Irbesartan Product Portfolio
- 4.22.5 Zhuhai Rundu Pharma Recent Developments
5 Global Irbesartan Market Scenario by Region
- 5.1 Global Irbesartan Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Irbesartan Sales by Region: 2021-2032
- 5.2.1 Global Irbesartan Sales by Region: 2021-2026
- 5.2.2 Global Irbesartan Sales by Region: 2027-2032
- 5.3 Global Irbesartan Revenue by Region: 2021-2032
- 5.3.1 Global Irbesartan Revenue by Region: 2021-2026
- 5.3.2 Global Irbesartan Revenue by Region: 2027-2032
- 5.4 North America Irbesartan Market Facts & Figures by Country
- 5.4.1 North America Irbesartan Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Irbesartan Sales by Country (2021-2032)
- 5.4.3 North America Irbesartan Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Irbesartan Market Facts & Figures by Country
- 5.5.1 Europe Irbesartan Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Irbesartan Sales by Country (2021-2032)
- 5.5.3 Europe Irbesartan Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Irbesartan Market Facts & Figures by Country
- 5.6.1 Asia Pacific Irbesartan Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Irbesartan Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Irbesartan Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Irbesartan Market Facts & Figures by Country
- 5.7.1 South America Irbesartan Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Irbesartan Sales by Country (2021-2032)
- 5.7.3 South America Irbesartan Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Irbesartan Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Irbesartan Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Irbesartan Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Irbesartan Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Irbesartan Sales by Type (2021-2032)
- 6.1.1 Global Irbesartan Sales by Type (2021-2032) & (Kg)
- 6.1.2 Global Irbesartan Sales Market Share by Type (2021-2032)
- 6.2 Global Irbesartan Revenue by Type (2021-2032)
- 6.2.1 Global Irbesartan Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Irbesartan Revenue Market Share by Type (2021-2032)
- 6.3 Global Irbesartan Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Irbesartan Sales by Application (2021-2032)
- 7.1.1 Global Irbesartan Sales by Application (2021-2032) & (Kg)
- 7.1.2 Global Irbesartan Sales Market Share by Application (2021-2032)
- 7.2 Global Irbesartan Revenue by Application (2021-2032)
- 7.2.1 Global Irbesartan Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Irbesartan Revenue Market Share by Application (2021-2032)
- 7.3 Global Irbesartan Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Irbesartan Value Chain Analysis
- 8.1.1 Irbesartan Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Irbesartan Production Mode & Process
- 8.2 Irbesartan Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Irbesartan Distributors
- 8.2.3 Irbesartan Customers
9 Global Irbesartan Analyzing Market Dynamics
- 9.1 Irbesartan Industry Trends
- 9.2 Irbesartan Industry Drivers
- 9.3 Irbesartan Industry Opportunities and Challenges
- 9.4 Irbesartan Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst